作者
Corrado Campochiaro, Emanuel Della-Torre, Giulio Cavalli, Giacomo De Luca, Marco Ripa, Nicola Boffini, Alessandro Tomelleri, Elena Baldissera, Patrizia Rovere-Querini, Annalisa Ruggeri, Giacomo Monti, Francesco De Cobelli, Alberto Zangrillo, Moreno Tresoldi, Antonella Castagna, Lorenzo Dagna, Toci-Raf Study Group
发表日期
2020/6/1
期刊
European journal of internal medicine
卷号
76
页码范围
43-49
出版商
Elsevier
简介
Background
Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however, limited data are available on the safety and efficacy.
Methods
We performed a retrospective study on severe COVID-19 patients with hyper-inflammatory features admitted outside intensive care units (ICUs). Patients treated with intravenous TCZ in addition to standard of care were compared to patients treated with standard of care alone. Safety and efficacy were assessed over a 28-day follow-up.
Results
65 patients were included. Among them, 32 were treated with TCZ. At baseline, all patients were on high-flow supplemental oxygen and most (78% of TCZ patients and 61% of standard treatment patients) were on non-invasive ventilation. During the 28-day follow-up, 69% of TCZ patients experienced a clinical improvement compared to 61 …
学术搜索中的文章
C Campochiaro, E Della-Torre, G Cavalli, G De Luca… - European journal of internal medicine, 2020